Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

253 Stolina, M., S. Sharma,Y. Lin, M. Dohadwala,
B. Gardner, J. Luo, L. Zhu,
M. Kronenberg, P. W. Miller, J. Portanova,
J. C. Lee and S. M. Dubinett.
2000. Specific inhibition of cyclooxygenase
2 restores antitumor reactivity
by altering the balance of IL-10 and IL-
12 synthesis. J. Immunol. 164: 361.
254 Lonnroth, C., M. Andersson and
K. Lundholm. 2001. Indomethacin
and telomerase activity in tumor
growth retardation. Int. J. Oncol. 18:
929.
255 Williams, C. S., M. Tsujii, J. Reese,
S. K. Dey and R. N. Dubois. 2000. Host
cyclooxygenase-2 modulates carcinoma
growth. J. Clin. Invest. 105: 1589.
256 Chulada, P. C., M. B. Thompson,
J. F. Mahler, C. M. Doyle, B. W. Gaul,
C. Lee, H. F. Tiano, S. G. Morham,
O. Smithies and R. Langenbach.
2000. Genetic disruption of Ptgs-1, as
well as Ptgs-2, reduces intestinal tumorigenesis
in Min mice. Cancer Res. 60:
4705.
257 Kawamori, T., C. V. Rao, K. Seibert
and B. S. Reddy. 1998. Chemopreventive
activity of celecoxib, a specific cyclooxygenase-2
inhibitor, against colon
carcinogenesis. Cancer Res. 58: 409.
258 Giardiello, F. M., J. A. Offerhaus,
A. C. Tersmette, L. M. Hylind,
A. J. Krush, J. D. Brensinger,
S. V. Booker and S. R. Hamilton.
1996. Sulindac induced regression of
colorectal adenomas in familial adenomatous
polyposis: evaluation of predictive
factors. Gut 38: 578.
259 Nugent, K. P., K. C. Farmer, A. D. Spigelman,
C. B. Williams and R. K. Phillips.
1993. Randomized controlled trial
of the effect of sulindac on duodenal and
rectal polyposis and cell proliferation in
patients with familial adenomatous polyposis.
Br. J. Surg. 80:1618.
260 Gately, S. 2000. The contributions of
cyclooxygenase-2 to tumor angiogenesis.
Cancer Metast. Rev. 19: 19.
261 Heby, O. 1981. Role of polyamines in
the control of cell proliferation and differentiation.
Differentiation 19:1.
262 Durie, B. G., S. E. Salmon and
D. H. Russell. 1977. Polyamines as
markers of response and disease activ-
References
ity in cancer chemotherapy. Cancer Res.
37: 214.
263 Uehara, N., K. Kita, S. Shirakawa,
H. Uchino and Y. Saeki. 1980. Elevated
polyamine content in erythrocytes
of malignant lymphoma patients. Gann
71: 393.
264 Heby, O. and G. Andersson. 1978. Tumour
cell death: the probable cause of
increased polyamine levels in physiological
fluids. Acta Pathol. Microbiol.
Scand. A 86: 17.
265 Nishioka, K., K. Ezaki and J. S. Hart.
1980. A preliminary study of polyamines
in the bone-marrow plasma of
adult patients with leukemia. Clin.
Chim. Acta 107: 59.
266 Romano, M., L. Cecco, M. Cerra, R.
Montuori and C. De Rosa. 1980. Polyamines
as biological markers of the effectiveness
of therapy in acute leukemia.
Tumori 66: 677.
267 Chamaillard, L.,V. Quemener, R. Havouis
and J. P. Moulinoux. 1993. Polyamine
deprivation stimulates natural
killer cell activity in cancerous mice.
Anticancer Res. 13: 1027.
268 Redgate, E. S., S. Boggs, A. Grudziak
and M. Deutsch. 1995. Polyamines in
brain tumor therapy. J. Neurooncol. 25:
167.
269 Porter, C. W. and J. R. Sufrin. 1986.
Interference with polyamine biosynthesis
and/or function by analogs of polyamines
or methionine as a potential anticancer
chemotherapeutic strategy. Anticancer
Res. 6: 525.
270 Casero, R. A. J., B. Go, H. W. Theiss,
J. Smith, S. B. Baylin and G. D. Luk.
1987. Cytotoxic response of the relatively
difluoromethylornithine-resistant
human lung tumor cell line NCI H157
to the polyamine analogue N 1 ,N 8 -bis(ethyl)spermidine.
Cancer Res. 47:
3964.
271 Herr, H. W., E. L. Kleinert,
P. S. Conti, J. H. Burchenal and
W. F. J. Whitmore. 1984. Effects of adifluoromethylornithine
and methylglyoxal
bis(guanylhydrazone) on the
growth of experimental renal adenocarcinoma
in mice. Cancer Res. 44: 4382.
272 Klein, S., J. J. Miret, I. D. Algranati
and E. S. de Lustig. 1985. Effect of a-
151